<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01263236</url>
  </required_header>
  <id_info>
    <org_study_id>14095</org_study_id>
    <secondary_id>I5J-MC-NOAA</secondary_id>
    <nct_id>NCT01263236</nct_id>
  </id_info>
  <brief_title>A Study of LY2940094 in Major Depressive Disorder</brief_title>
  <official_title>A Phase I, Double-Blind, Placebo Controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study of LY2940094 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BlackThorn Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BlackThorn Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and tolerability of ascending single
      and multiple oral doses of LY2940094 in healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with clinically significant effects</measure>
    <time_frame>Baseline to study completion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LY2940094, maximal concentration (Cmax)- single dose</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LY2940094, area under the concentration-time curve (AUC)- single dose</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LY2940094, maximal concentration (Cmax) - multiple dose</measure>
    <time_frame>pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 hours postdose on day 1, predose on days 2-6, predose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 hours postdose on day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LY2940094, area under the concentration-time curve (AUC)- multiple dose</measure>
    <time_frame>pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 hours postdose on day 1, predose on days 2-6, predose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 hours postdose on day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>LY2940094 - single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 2-800 milligram (mg) LY2940094</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2940094 - multiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral dose of 2-200 mg LY2940094 for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose or daily oral dose for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2940094</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY2940094 - single dose</arm_group_label>
    <arm_group_label>LY2940094 - multiple dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males of any ethnic origin.

          -  Have a body mass index (BMI) between 19.0 and 30.0 kilogram/square meter (kg/mÂ²),
             inclusive.

          -  Must be in good health, as determined by a medical history, physical examination,
             12-lead electrocardiogram (ECG) and clinical laboratory evaluations.

          -  Have a calculated creatinine clearance of greater than 70 milliliter/minute (mL/min).

          -  Have venous access sufficient to allow blood sampling as per the protocol.

          -  Will have given their written informed consent to participate in the study and to
             abide by the study restrictions.

        Exclusion Criteria:

          -  Male subjects who are not, or whose partners are not willing to use appropriate
             contraception from the time of the first dose until 3 months after the final dosing
             occasion.

          -  Have received any prescribed systemic or topical medication within 14 days of the
             first dose administration

          -  Have used any non-prescribed systemic or topical medication (including herbal
             remedies) within 7 days of the first dose administration (with the exception of
             vitamin/mineral supplements) unless in the opinion of the Investigator the medication
             will not interfere with the study procedures or compromise safety.

          -  Have received any medications, including St John's Wort, known to chronically alter
             drug absorption or elimination processes within 30 days of the first dose
             administration

          -  Currently enrolled in, have completed or discontinued within the last 30 days from, a
             clinical trial involving an investigational product or are concurrently enrolled in
             any other type of medical research judged not to be scientifically or medically
             compatible with this study.

          -  Have donated or lost 50 to 499 milliliter (mL) of whole blood within 30 days, or more
             than 499 milliliter (mL) whole blood within 56 days preceding first dose
             administration.

          -  Have a significant history of drug allergy as determined by the Investigator.

          -  Have any clinically significant allergic disease (excluding non-active hay fever), or
             any known allergy to LY2940094 or excipients as determined by the Investigator.

          -  Have a semi-reclined blood pressure and pulse rate higher than 130/90 millimeters of
             mercury (mmHg) and 100 beats per minute (bpm), respectively, or lower than 90/50
             millimeters of mercury (mmHg) and 40 beats per minute (bpm), respectively.

          -  Consume more than 28 units of alcohol per week or who have a significant history of
             alcoholism or drug/chemical abuse/dependence as determined by the Investigator.

          -  Have a positive urine drug screen or alcohol breath test result that indicates
             substance abuse at screening or at admission to any treatment period.

          -  Smoke more than 10 cigarettes or the equivalent in tobacco per day and willing to
             avoid smoking for durations of at least 10 hours.

          -  With, or with a history of, any clinically significant neurological, gastrointestinal,
             renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine,
             hematological or other major disorders as determined by the Investigator.

          -  Have had a clinically significant illness within 4 weeks of the start of dose
             administration as determined by the Investigator.

          -  Have serum hepatitis, or who are carriers of the hepatitis B surface antigen (HBsAg)
             or hepatitis C antibody, or who have a positive result to the test for human
             immunodeficiency virus (HIV) antibodies.

          -  Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the
             investigator, increases the risk of participating in the study. In addition, subjects
             with the following findings will be excluded:

               -  Confirmed Bazett's corrected QT (QTcB) interval greater than 450 millisecond
                  (msec) in 2 of 3 electrocardiograms (ECGs).

               -  Bundle branch blocks and other conduction abnormalities (including 2nd or 3rd
                  degree Atrioventricular block, complete left bundle branch block, complete right
                  bundle branch block or Wolffe-Parkinson-White Syndrome, defined as PR less than
                  110 milliseconds (msec),confirmed by a repeat electrocardiogram [ECG]) other than
                  mild first-degree atrioventricular block (AV) block.

               -  Irregular rhythms other than sinus arrhythmia or occasional rare supraventricular
                  ectopic beats.

               -  History of unexplained syncope.

               -  Family history of unexplained syncope or sudden death due to long QT syndrome.

               -  T wave configurations are not of adequate quality for assessing QTc intervals.

          -  Have previously completed or been withdrawn from this study.

          -  Taking any excluded medications that cannot be discontinued at Screening.

          -  Have a personal or family history of recurrent seizures or complicated febrile
             seizures.

          -  Have a history of significant brain trauma.

          -  Have epileptiform activity on baseline electroencephalogram (EEG).

        The following exclusion criteria apply only to those subjects enrolling in the part of the
        study involving lumbar puncture (LP) procedures

          -  Have abnormalities in lumbar spine as determined by the investigator

          -  Have a history of clinically significant back pain and/or back injury

          -  Have evidence or history of significant active bleeding or coagulation disorder

          -  Have an allergy to lidocaine (XylocaineÂ®) or its derivatives

          -  Have medical or surgical conditions in which LP is contraindicated The following
             exclusion criterion applies only to those subjects enrolling in the part of the study
             involving alcohol interaction Have an intolerance or allergy toward alcohol (symptoms
             may include nausea, flushed face, vomiting, or hypotension) or who, in the opinion of
             the investigator, may not be able to tolerate 0.8 gram per kilogram (g/kg) alcohol
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5V 2T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2010</study_first_submitted>
  <study_first_submitted_qc>December 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2010</study_first_posted>
  <last_update_submitted>February 1, 2017</last_update_submitted>
  <last_update_submitted_qc>February 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

